First atomic-level view of ‘marijuana receptor’
By Scripps Research Institute
In a discovery that advances the understanding of how marijuana works in the human body, an international group of scientists, including those from the Florida campus of The Scripps Research Institute (TSRI), have for the first time created a three-dimensional atomic-level image of the molecular structure activated by tetrahydrocannabinol (THC), the active chemical in marijuana.
By Scripps Research Institute
The new insights into the human cannabinoid receptor 1 (CB1) will provide an essential tool for understanding why some molecules related to THC have unexpectedly complex and sometimes harmful effects. The findings also have the potential to guide drug design for pain, inflammation, obesity, fibrosis and other indications.
The new study, published by the journal Cell, was led by a quartet of scientists: TSRI’s Laura Bohn, Northeastern University’s Alexandros Makriyannis, Shanghai Tech University’s Zhi-Jie Liu and Shanghai Tech and University of Southern California’s Raymond C. Stevens.
THE CHALLENGE TO PRODUCE A CRYSTAL FORM
At the beginning of the study, the team struggled to produce a crystal form – needed to obtain data to recreate the high-resolution structure – of the receptor bound with AM6538, a stabilizing a molecule that blocks the receptor’s action.
“The CB1 receptor proved as challenging for crystallization as it did for understanding its functional regulation and signaling,” said Bohn, who is a professor in TSRI’s department of molecular therapeutics.
When the scientists succeeded in crystalizing the receptor and collecting the data, the structure of the cannabinoid receptor complex revealed an expansive and complicated binding pocket network consisting of multiple sub-pockets and channels to various regions of the receptor.
Cannabinoid receptors are part of a large class of receptors known as G protein-coupled receptors (GPCR), which account for about 40 per cent of all prescription pharmaceuticals on the market and play key roles in many physiological functions. When an outside substance binds to a GPCR, it activates a G protein inside the cell to release components and create a specific cellular response.
AM6538, is an antagonist/inverse agonist that binds tightly to the receptor; it has a long half-life, making it potentially useful as a treatment of addiction disorders.
“As marijuana continues to become more common in society, it is critical that we understand how it works in the human body,” said Liu, who is professor and deputy director of the iHuman Institute of Shanghai Tech and is also affiliated with the Chinese Academy of Sciences.
The first author of the Cell study, “Crystal Structure of the Human Cannabinoid Receptor CB1,” is Tian Hua of Shanghai Tech University and the Chinese Academy of Sciences (Beijing).
In addition to Stevens, Liu, Bohn, Makriyannis and Hua, other authors of the study are Mengchen Pu, Lu Qu, Yiran Wu, Suwen Zhao, Wenqing Shui, Shanshan Li of iHuman Institute at ShanghaiTech University; Nikolai Zvonok, Anisha Korde, Kiran Vemuri of Northeastern University; Gye Won Han of University of Southern California; Robert Laprairie, Edward Stahl, and Jo-Hao Ho (graduate student) of TSRI; Irina Kufareva of University of California, San Diego; and Michael Hanson of the GPCR Consortium.
The study was supported by the Ministry of Science and Technology of China (grants 2014CB910400 and 2015CB910104), National Nature Science Foundation of China (grant 31330019), National Institutes of Health (grants P01DA009158, R37DA023142 and R01AI118985), the National Science Foundation, Shanghai Municipal Government, ShanghaiTech University and the GPCR Consortium.
Full bibliographic information: “Crystal Structure of the Human Cannabinoid Receptor CB1”; Tian Hua, Kiran Vemuri, Mengchen Pu, Lu Qu, Gye Won Han, Yiran Wu1, Suwen Zhao, Wenqing Shui, Shanshan Li, Anisha Korde, Robert B. Laprairie, Edward L. Stahl, Jo-Hao Ho, Nikolai Zvonok, Han Zhou, Irina Kufareva, Beili Wu, Qiang Zhao, Michael A. Hanson, Laura M. Bohn, Alexandros Makriyannis, Raymond C. Stevens, Zhi-Jie Liu; Cell; DOI: dx.doi.org/10.1016/j.cell.2016.10.004; Online Publication Date: 20 October 2016
ABOUT SCRIPPS RESEARCH INSTITUTE
The Scripps Research Institute (TSRI) is one of the world’s largest independent, not-for-profit organizations focusing on research in the biomedical sciences.
TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases.
An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists – including two Nobel laureates and 20 members of the National Academy of Science, Engineering or Medicine – work toward their next discoveries. The institute’s graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation.
For more information, see www.scripps.edu.